FGF20
Basic information
Region (hg38): 8:16992181-17002345
Links
Phenotypes
GenCC
Source:
- bilateral renal agenesis (Supportive), mode of inheritance: AR
- renal hypodysplasia/aplasia 2 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Renal hypodysplasia/aplasia 2 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Renal | 22698282 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FGF20 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 15 | 19 | ||||
missense | 42 | 47 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 0 | |||||
non coding | 11 | 12 | ||||
Total | 0 | 1 | 45 | 18 | 18 |
Variants in FGF20
This is a list of pathogenic ClinVar variants found in the FGF20 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
8-16992890-G-A | Parkinson disease, late-onset | Benign (Jun 19, 2021) | ||
8-16992907-A-G | Benign (Jun 18, 2021) | |||
8-16992989-C-G | Benign (Nov 11, 2018) | |||
8-16993078-G-A | Likely benign (Dec 22, 2023) | |||
8-16993085-A-G | not specified | Uncertain significance (Jan 17, 2023) | ||
8-16993092-C-A | Uncertain significance (Jul 05, 2022) | |||
8-16993092-C-T | Benign (Jan 19, 2024) | |||
8-16993098-A-G | not specified | Uncertain significance (Sep 27, 2022) | ||
8-16993125-C-G | not specified | Uncertain significance (Jun 24, 2022) | ||
8-16993162-C-G | Uncertain significance (Aug 10, 2023) | |||
8-16993173-C-A | Uncertain significance (Jun 14, 2023) | |||
8-16993174-G-A | FGF20-related disorder | Likely benign (Apr 20, 2020) | ||
8-16993185-G-C | Benign (Jul 17, 2023) | |||
8-16993204-T-G | Likely benign (Sep 06, 2023) | |||
8-16993239-T-C | not specified | Uncertain significance (Mar 02, 2023) | ||
8-16993242-A-G | not specified | Uncertain significance (Jan 26, 2022) | ||
8-16993244-A-G | not specified | Uncertain significance (Feb 06, 2023) | ||
8-16993261-G-C | not specified | Uncertain significance (Oct 29, 2021) | ||
8-16993296-T-C | Uncertain significance (Sep 19, 2023) | |||
8-16993311-G-C | not specified | Uncertain significance (Jan 16, 2024) | ||
8-16993315-C-G | Uncertain significance (Jul 22, 2023) | |||
8-16993318-C-T | Renal hypodysplasia/aplasia 2 | Likely pathogenic (May 28, 2019) | ||
8-16993331-G-C | Likely benign (Mar 22, 2023) | |||
8-16993369-T-G | Benign (Jun 20, 2021) | |||
8-16993428-G-T | Benign (Jun 19, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
FGF20 | protein_coding | protein_coding | ENST00000180166 | 3 | 10013 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.814 | 0.182 | 123721 | 0 | 3 | 123724 | 0.0000121 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.874 | 121 | 96.8 | 1.25 | 0.00000468 | 1299 |
Missense in Polyphen | 39 | 38.934 | 1.0017 | 457 | ||
Synonymous | -1.46 | 51 | 39.3 | 1.30 | 0.00000199 | 414 |
Loss of Function | 2.18 | 0 | 5.55 | 0.00 | 2.30e-7 | 87 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Neurotrophic factor that regulates central nervous development and function. {ECO:0000269|PubMed:16597617}.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Gastric cancer - Homo sapiens (human);Melanoma - Homo sapiens (human);Breast cancer - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Rap1 signaling pathway - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hair Follicle Development- Induction (Part 1 of 3);MAPK Signaling Pathway;ESC Pluripotency Pathways;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Regulation of Actin Cytoskeleton;FGFR2c ligand binding and activation;FGFR2 ligand binding and activation;FRS-mediated FGFR2 signaling;Negative regulation of FGFR2 signaling;Signaling by FGFR2;FGFR3b ligand binding and activation;Phospholipase C-mediated cascade; FGFR2;FGFR3c ligand binding and activation;SHC-mediated cascade:FGFR2;FRS-mediated FGFR3 signaling;PI-3K cascade:FGFR2;Downstream signaling of activated FGFR2;SHC-mediated cascade:FGFR3;PI-3K cascade:FGFR4;PI-3K cascade:FGFR3;Downstream signaling of activated FGFR3;Disease;Negative regulation of FGFR3 signaling;Signaling by FGFR3;FGFR4 ligand binding and activation;Signal Transduction;FRS-mediated FGFR4 signaling;SHC-mediated cascade:FGFR4;Downstream signaling of activated FGFR4;Negative regulation of FGFR4 signaling;Signaling by FGFR4;Signaling by FGFR;FGFR3 ligand binding and activation;FGFR3 mutant receptor activation;PI3K Cascade;IRS-mediated signalling;Insulin receptor signalling cascade;Activated point mutants of FGFR2;Signaling by Insulin receptor;GPCR signaling-G alpha q;GPCR signaling-cholera toxin;GPCR signaling-pertussis toxin;FGF;Signaling by FGFR2 in disease;GPCR signaling-G alpha s Epac and ERK;GPCR signaling-G alpha s PKA and ERK;Signaling by activated point mutants of FGFR3;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;PIP3 activates AKT signaling;PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling;Negative regulation of the PI3K/AKT network;FGFR2 mutant receptor activation;Signaling by FGFR3 point mutants in cancer;Signaling by FGFR3 in disease;Signaling by FGFR in disease;Constitutive Signaling by Aberrant PI3K in Cancer;PI3K/AKT Signaling in Cancer;GPCR signaling-G alpha i;IRS-related events triggered by IGF1R;IGF1R signaling cascade;Signaling by activated point mutants of FGFR1;FGFR1 mutant receptor activation;Signaling by FGFR1 in disease;Signaling by Receptor Tyrosine Kinases;Intracellular signaling by second messengers;Phospholipase C-mediated cascade: FGFR1;Diseases of signal transduction;Downstream signaling of activated FGFR1;Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R);FGFR1c ligand binding and activation;FGFR1 ligand binding and activation;FRS-mediated FGFR1 signaling;SHC-mediated cascade:FGFR1;PI-3K cascade:FGFR1;Negative regulation of FGFR1 signaling;Signaling by FGFR1;Phospholipase C-mediated cascade; FGFR3;Phospholipase C-mediated cascade; FGFR4
(Consensus)
Recessive Scores
- pRec
- 0.230
Haploinsufficiency Scores
- pHI
- 0.729
- hipred
- Y
- hipred_score
- 0.558
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.343
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Fgf20
- Phenotype
- hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Zebrafish Information Network
- Gene name
- fgf20b
- Affected structure
- pharyngeal arch cartilage
- Phenotype tag
- abnormal
- Phenotype quality
- decreased size
Gene ontology
- Biological process
- MAPK cascade;signal transduction;cell-cell signaling;positive regulation of cell population proliferation;fibroblast growth factor receptor signaling pathway;regulation of signaling receptor activity;regulation of dopamine secretion;peptidyl-tyrosine phosphorylation;phosphatidylinositol-3-phosphate biosynthetic process;negative regulation of neuron apoptotic process;phosphatidylinositol phosphorylation;positive regulation of protein kinase B signaling;regulation of cardiac muscle cell proliferation;inner ear receptor cell differentiation;positive regulation of ERK1 and ERK2 cascade;positive regulation of dopaminergic neuron differentiation
- Cellular component
- extracellular region
- Molecular function
- protein tyrosine kinase activity;Ras guanyl-nucleotide exchange factor activity;signaling receptor binding;fibroblast growth factor receptor binding;growth factor activity;1-phosphatidylinositol-3-kinase activity;heparan sulfate proteoglycan binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity;receptor-receptor interaction